We currently have three products in our pipeline, each addressing aspects of late-stage liver disease that do not have effective pharmacological therapies and where standard care pathways are not scalable nor sufficiently effective in managing the disease. Our products undergo rigorous clinical trials, providing real-world evidence and proving their efficacy in addressing their specific purposes.
Two of our products have completed Phase 2-equivalent PoCs, of which one has already entered a Pivotal RCT.